Regeneron Pharmaceuticals (REGN) Q3 FY2026 Earnings Call

Bottom line

The sleeper story here isn't Dupixent's record quarter, it's that REGN's headline 36% revenue growth and 70% EPS growth are stacked with one-time and structural accounting tailwinds: a $60M Alaris catch-up management admits 'will not recur', the first full quarter of Sanofi profit share post-debt-payoff, and a $1B upfront that lands entirely in Q4, setting up an even messier comp next quarter. The obvious headline, 'EYLEA HD hits new highs,' is true but misleading: the combined retinal franchise is actually down 1% YoY because legacy EYLEA is collapsing 41% amid biosimilar competition, the binding constraint is cannibalization and payer dynamics, not physician demand. Management's own words give away the real posture on the Sanofi next-gen pipeline: 'I don't think this is the format where we really want to unveil our strategy', a classic scope-narrowing dodge on the exact unit-economics question (franchise expansion vs. replacement) that matters most for modeling Dupixent's long-term moat. My view changes if Q4 organic collaboration revenue growth, stripped of the $1B upfront and the Sanofi profit-share step-up, comes in meaningfully below the headline number, or if the GA data slip from Q4 2026 to early 2027 turns out to be the first of several ophthalmology pipeline delays.

The 30-second version

The 36% growth number has at least $1B+ of one-time/structural sugar baked in
'Record' EYLEA HD masks a retinal franchise that's actually shrinking
Gross margin disclosure quietly vanished from the call

What changed this quarter

Metric	Q2'26	Q3'26	Change
Total Revenue	$4.3B, +17% YoY	$5.1B, +36% YoY	Growth rate more than doubled, partly non-organic
Non-GAAP Diluted EPS	$14.29, +11% YoY	$20.07, +70% YoY	Massive acceleration, boosted by full Sanofi profit share
Net Income	$1.5B	$2.2B	+47% QoQ
Sanofi Collaboration Revenue	$2.2B all-time high, +59% YoY	$2.7B all-time high, +77% YoY	Inflated by first full quarter of profit share post debt payoff
Dupixent Global Net Sales	$6.0B, +38% cc	$6.5B, +35% cc	Growth rate decelerating despite record dollars
EYLEA HD US Net Sales	$596M, +52% YoY	$700M, +62% YoY	Accelerating, but cannibalizing legacy EYLEA
EYLEA (legacy) US Net Sales	$412M, -45% YoY	$400M, -41% YoY	Still collapsing, biosimilar pressure intensifying
Combined Retinal Franchise	~$1.0B, +7% QoQ	$1.1B, -1% YoY	Franchise-level growth negative despite HD records
Libtayo Global Net Sales	$489M, +29% cc	$550M, +51% cc	Accelerating, run-rate now ~$2.2B
R&D Expense	$1.5B	$1.7B	+13% QoQ, 2027 guide mid-teens % growth

Accountability tracked

14 new promises made4 narrative shifts flagged7 prior promises scored

Inside the full report

The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.

Read the full REGN Q3'26 report Subscribe

Regeneron Pharmaceuticals (REGN)

The 30-second version

What changed this quarter

Accountability tracked

Follow what management promises next